The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Ras mediates cell proliferation, survival and differentiation. Mutations in K-Ras4B are predominant at residues G12, G13 and Q61. Even though all impair GAP-assisted GTP → GDP hydrolysis, the mutation frequencies of K-Ras4B in human cancers vary. Here we aim to figure out their mechanisms and differential oncogenicity. In total, we performed 6.4 μs molecular dynamics simulations on the wild-type K-Ras4B (K-Ras4B WT-GTP/GDP) catalytic domain, the K-Ras4B WT-GTP–GAP complex, and the mutants (K-Ras4B G12C/G12D/G12V-GTP/GDP, K-Ras4B G13D-GTP/GDP, K-Ras4B Q61H-GTP/GDP) and their complexes with GAP. In addition, we simulated ‘exchanged’ nucleotide states. These comprehensive simulations reveal that in solution K-Ras4B WT-GTP exists in two, active and inactive, conformations. Oncogenic mutations differentially elicit an inactive-to-active conformational transition in K-Ras4B-GTP; in K-Ras4B G12C/G12D-GDP they expose the bound nucleotide which facilitates the GDP-to-GTP exchange. These mechanisms may help elucidate the differential mutational statistics in K-Ras4B-driven cancers. Exchanged nucleotide simulations reveal that the conformational transition is more accessible in the GTP-to-GDP than in the GDP-to-GTP exchange. Importantly, GAP not only donates its R789 arginine finger, but stabilizes the catalytically-competent conformation and pre-organizes catalytic residue Q61; mutations disturb the R789/Q61 organization, impairing GAP-mediated GTP hydrolysis. Together, our simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent mutant forms were KRASG12D (41%), KRASG12V (28%), and KRASG12C (14%).49”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [16]
In the citing paper
“The total simulation times of these studies were in the range of 1–8 μs, which is reasonable but likely not sufficient to unravel long-time dynamics associated with slow conformational changes.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 41,298
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Cited by
Items 101–200 of 225
ROS regulation of RAS and vulva development in Caenorhabditis elegans
Kramer‐Drauberg, M., Liu, J., Desjardins, D., Wang, Y., Branicky, R. S., & Hekimi, S. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008838 · Cited by 19
“Such oncogenic mutations at G13 (Fig 1B and S1 Fig) favor the active GTP-bound state [45, 46].”
BackgroundHsu, A. P. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad001 · Cited by 20
Dynamic Protein Allosteric Regulation and Disease
Nussinov, R., Tsai, C.-J., & Jang, H. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8719-7_2 · Cited by 18
Self-citationTisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 19
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 19
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C. E., et al. (2025) · Blood · doi:10.1182/blood.2025030558 · Cited by 18
Kazi, A., Ranjan, A., Vasantha Kumar, M. V., Agianian, B., Chavez, M. G., Vudatha, V., Wang, R., Vangipurapu, R., Chen, L., Kennedy, P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0222 · Cited by 17
Alcantara, K. M. M., Malapit, J. R. P., Yu, R. T. D., Garrido, J. A. M. G., Rigor, J. P. T., Angeles, A. K., la Paz, E. M. C., & Garcia, R. L. (2019) · Cells · doi:10.3390/cells8121557 · Cited by 16
“Such shifts in atomic interactions likely cause the functional impact of the G12D canonical mutation on KRAS intrinsic GTP-hydrolysis, consistent with previous reports as increased charged interactions between amino acid residue D12 and GTP theoretically prolongs the retention of KRAS in the GTP-bound active state [42…”
BackgroundA novel RAC2 variant presenting as severe combined immunodeficiency
Stern, H., Donkó, A., Shapiro, T., Hsu, A. P., Leto, T. L., Holland, S. M., & Andreae, D. A. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00915-2 · Cited by 15
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity
Zhao, H., Li, L., Liu, J., Mai, R., Chen, J., & Chen, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105652 · Cited by 16
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 18
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 18
“However, developing small-molecule inhibitors of KRAS has been notoriously difficult, such that KRAS has until recently been dubbed “undruggable” [6, 7].”
Conditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling
Lee, S., & Lee, K. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316942 · Cited by 15
Hu, F., Wang, Y., Zeng, J., Deng, X., Xia, F., & Xu, X. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c07666 · Cited by 15
Li, A., Li, S., Wang, P. G., Dang, C., Fan, X. M., Chen, M., Liu, D., Li, F., Liu, H., Zhang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02939 · Cited by 19
Rationale for RAS Mutation-Tailored Therapies
Montalvo, S. K., Li, L., & Westover, K. D. (2016) · Future Oncology · doi:10.2217/fon-2016-0363 · Cited by 15
Zeng, J., Chen, J., Xia, F., Cui, Q., Deng, X., & Xu, X. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp00274d · Cited by 15
Roux, Ö. L., Pershing, N. L., Kaltenbrun, E., Newman, N. J., Everitt, J. I., Baldelli, E., Pierobon, M., Petricoin, E. F., & Counter, C. M. (2022) · eLife · doi:10.7554/elife.75715 · Cited by 15
Mou, L., Cui, T., Liu, W., Zhang, H., Cai, Z., Lu, S., & Gao, G. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12895 · Cited by 15
Self-citationNMR in integrated biophysical drug discovery for RAS: past, present, and future
Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 16
Shakeel, I., Haider, S., Khan, S., Ahmed, S., Hussain, A., Alajmi, M. F., Chakrabarty, A., Afzal, M., & Hassan, M. I. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117123 · Cited by 18
Tripathi, R., Noetzel, J., & Marx, D. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp06343e · Cited by 14
Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect
He, X., Du, K., Wang, Y., Fan, J., Li, M., Ni, D., Lu, S., Bian, X., & Liu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.860962 · Cited by 13
“The initial parameter files for minimization and simulation were prepared using Amber18 package with the ff14SB force field (Maier et al., 2015) and the general Amber force field (GAFF) (Wang et al., 2004; Lu et al., 2016b; Wang et al., 2021a).”
BackgroundMethodSelf-citationMulti-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors
Poorebrahim, M., Abazari, M. F., Moradi, L., Shahbazi, B., Mahmoudi, R., Kalhor, H., Askari, H., & Teimoori‐Toolabi, L. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009962 · Cited by 13
“Moreover, interactions between T35 and G60 with the γphosphate of GTP stabilize the ‘active’ state of the nucleotide-protein complex [27].”
BackgroundResultInfluentialActivation Mechanism of RhoA Caused by Constitutively Activating Mutations G14V and Q63L
Chen, S., Zhang, Z., Zhang, Y., Choi, T., & Zhao, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415458 · Cited by 15
“The active state exhibited a tightly closed conformation of switch I and II, characterized by two highly conserved hydrogen bonds formed by GTP’s γ-phosphate to T35 (T37 in RhoA) and G60 (G62 in RhoA), whereas the inactive state contained three substates 1, 2, and 3, described by the loss of both γphosphate-mediated i…”
BackgroundInfluentialShi, S., Zheng, L., Ren, Y., & Wang, Z. (2023) · Molecules · doi:10.3390/molecules28072886 · Cited by 13
Liang, F., Kang, Z., Sun, X., Chen, J., Duan, X., He, H., & Cheng, J. (2023) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-023-00498-1 · Cited by 12
“The “inactive” and “active” conformations were reported in GppNHp-bound HRAS [51, 52] and in wild-type GTPbound KRAS4B [50].”
BackgroundInfluentialLuchini, C., Mattiolo, P., Baştürk, O., Mafficini, A., Özcan, K., Lawlor, R. T., Hong, S., Brosens, L. A. A., Marchegiani, G., Pea, A., et al. (2023) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002017 · Cited by 13
“#19 25 F Tail D-SP 22 UL-TW, smooth internal surface AE – AF (24)”
BackgroundJani, V., Sonavane, U., & Joshi, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36161 · Cited by 15
“It has been also observed by researchers that different mutations in the KRAS protein distinctly alter its GPTase activity or its affinity for downstream effector proteins [30 – 33].”
BackgroundDifferences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations
Kun, E., Tsang, Y. T. M., Lin, S., Pan, S., Medapalli, T., Malpica, A. L., Richards, J. S., Gershenson, D. M., & Wong, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77666-y · Cited by 13
Molecular dynamics simulations reveal the activation mechanism of mutations G12V and Q61L of Cdc42
Chen, S., Shu, L., Zhao, R., & Zhao, Y. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26320 · Cited by 11
Kumar, S. U., Varghese, R. P., Preethi, V. A., Doss, C. G. P., & Zayed, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811288 · Cited by 14
“(2016) [55], K-Ras-G12 mutations account for 89% of all human malignancies, while G13 and Q61 mutations account for 9% and 1%, respectively.”
BackgroundTripathi, S., Dsouza, N. R., Urrutia, R. A., & Zimmermann, M. T. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa972 · Cited by 12
Liu, Y., Zhang, W., Jang, H., & Nussinov, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02022 · Cited by 10
Self-citationKim, H., Gasmi-Seabrook, G. M. C., Uchida, A., Gebregiworgis, T., Marshall, C. B., & Ikura, M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169162 · Cited by 12
Xiao, S., Alshahrani, M., Hu, G., Tao, P., & Verkhivker, G. M. (2025) · Protein Science · doi:10.1002/pro.70228 · Cited by 11
Hartner, S., Abolfathi, H., Rezanejad, M., Liu, B., Karimi, E., Rogers, D., Sorin, M., Doré, S., Desharnais, L., Orain, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63465-4 · Cited by 13
Cluster analysis on conformational changes of the GDP/KRAS complex induced by A59G and D33E
Zhao, J., Wang, L., Bao, H., & Chen, J. (2021) · Chemical Physics Letters · doi:10.1016/j.cplett.2021.138995 · Cited by 10
Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline
Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 10
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer
Goldberg, S. B., & Herbst, R. S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00288-x · Cited by 9
KRAS G12C inhibition and innate immune targeting
Tani, T., Kitajima, S., Conway, E. B., Knelson, E. H., & Barbie, D. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1902991 · Cited by 11
“The three commonly observed missense mutations in KRAS: G12, G13, and Q61, impair GAP binding [4], forcing it to”
BackgroundWavelet coherence phase analysis decodes the universal switching mechanism of Ras GTPase superfamily
Motiwala, Z., Sandholu, A., Sengupta, D., & Kulkarni, K. A. (2023) · iScience · doi:10.1016/j.isci.2023.107031 · Cited by 8
Shakeel, I., Khan, S., Roy, S., Sherwani, F., Ahmad, S. F., Sohal, S. S., Afzal, M., & Hassan, M. I. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127036 · Cited by 9
Studying early structural changes in SOS1 mediated KRAS activation mechanism
Bhadhadhara, K., Jani, V., Koulgi, S., Sonavane, U., & Joshi, R. (2023) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2023.100115 · Cited by 10
“RAS protein belongs to the GTPase family of proteins and plays an important role in various cellular activities like cell proliferation, survival and differentiation (Mu ˜ noz-Maldonado et al., 2019; Lukman et al., 2010; Pantsar, 2020; Lu et al., 2016; Murugan et al., 2019).”
BackgroundAllosteric Activation of RhoA Complexed with p115-RhoGEF Deciphered by Conformational Dynamics
Haspel, N., Jang, H., & Nussinov, R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01412 · Cited by 9
Self-citationTisi, R., Spinelli, M., Palmioli, A., Airoldi, C., Cazzaniga, P., Besozzi, D., Nobile, M. S., Mazzoleni, E., Arnhold, S., GIOIA, L. D., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.625979 · Cited by 9
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Ebia, M., Blais, E. M., Cui, Y. Y., Petricoin, E. F., Pishvaian, M. J., Gaddam, S., Gong, J., Osipov, A., & Hendifar, A. E. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00684 · Cited by 7
Clinical Actionability of Genes in Gastrointestinal Tumors
Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7
“With HRAS and NRAS, KRAS is part of the RAS family and it cycles between inactive (GDP-bound in this form) and active GTP-bound states, regulated by GTPase-activating proteins (GAPs, e.g., NF1) and guanine nucleotide exchange factors (GEFs, e.g., SOS1) [142,143].”
Alshahrani, M., Parikh, V., Foley, B., Hu, G., & Verkhivker, G. M. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00966a · Cited by 7
RASpecting the oncogene: New pathways to therapeutic advances
Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7
Adeniji, E. A., Olotu, F. A., & Soliman, M. E. S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180718110231 · Cited by 7
Polyakov, I. V., & Nemukhin, A. V. (2023) · Biophysica · doi:10.3390/biophysica3020025 · Cited by 7
“Such a position of Q61 is inconsistent with the key role of this glutamine residue in the GTP hydrolysis by Ras-GAP complexes as confirmed by mutational studies [3,5,8].”
BackgroundStructural Dynamics of Rho GTPases
Lin, Y., & Zheng, Y. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168919 · Cited by 6
Iruthayaraj, A., Sakayanathan, P., Ameén, F., & Loganathan, C. (2024) · Journal of Molecular Recognition · doi:10.1002/jmr.3103 · Cited by 6
“G12D mutant is the reason for large exposure of nucleotide binding site [42] whereas; MRTX1133 utilizes the same and creates a sophisticated room for its binding.”
Sequence-defined phosphoestamers for selective inhibition of the KRAS G12D /RAF1 interaction
Claringbold, B., Vance, S., Paul, A. R., Williamson, J., Garrett, M. D., & Serpell, C. J. (2024) · Chemical Science · doi:10.1039/d4sc07218a · Cited by 6
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Classification of GTP-dependent K-Ras4B active and inactive conformational states
Narayan, B., Kiel, C., & Buchete, N. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0139181 · Cited by 6
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy
Jiang, M., Ma, S., Xuan, Y., & Chen, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117626 · Cited by 6
An Unusual Endometrial Stromal Neoplasm With JAZF1-BCORL1 Rearrangement
Moghaddam, P. A., Young, R. H., Ismiil, N. D., Bennett, J. A., & Oliva, E. (2023) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000941 · Cited by 6
YB-1 activating cascades as potential targets in KRAS-mutated tumors
Khozooei, S., Veerappan, S., & Toulany, M. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02092-8 · Cited by 6
Pan, Y., Yan, C., Hu, Y., Fan, Y., Pan, Q., Wan, Q., Torcivia-Rodriguez, J., & Mazumder, R. (2017) · Scientific Reports · doi:10.1038/srep42169 · Cited by 6
“SNVs on this residue disturb Ras signaling control and eventually trigger tumorigenesis by activate genes involved in cell growth, differentiation and survival 60 .”
Xiao, S., Alshahrani, M., Hu, G., Tao, P., & Verkhivker, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.27.635141 · Cited by 6
ELOVL6 activity attenuation induces mutant KRAS degradation
Hu, X., Atwal, R. S., Xiao, S., Ahmed, S. U., Wang, Z., Zhao, C., Wang, H., & Kelley, S. O. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01998-x · Cited by 6
Discoveries in the redox regulation of KRAS
Kramer‐Drauberg, M., & Ambrogio, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105901 · Cited by 6
Song, J., Wang, B., Zou, M., Zhou, H., Ding, Y., Ren, W., Fang, L., & Zhang, J. (2025) · Biology · doi:10.3390/biology14050477 · Cited by 5
Self-citationZeng, J., Li, L., Sun, C., Shen, S., Tan, Y., Chen, J., Xia, F., Deng, X., & Xu, X. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c01781 · Cited by 4
Assessing the Performance of BioEmu in Understanding Protein Dynamics
Zha, J., Li, N., Li, M., Liu, X., Zhu, R., Feng, L., Lu, X., & Zhang, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062896 · Cited by 9
“This is because many disease-causing mutations may not significantly change static structures but would alter the distribution of conformational ensemble [65].”
Self-citationMaki, H., Ayabe, R. I., Haddad, A., Nishioka, Y., Newhook, T. E., Cao, H. S. T., Chun, Y. S., Tzeng, C.-W. D., & Vauthey, J. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16822-4 · Cited by 4
“38,39 The reason KRAS G12V in particular syner-gizes with mutant TP53 is uncertain.”
Molecular Dynamics Investigation into the Stability of KRas and CRaf Multimeric Complexes
Geng, C., Zeng, J., Deng, X., Xia, F., & Xu, X. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c08767 · Cited by 4
Li, J., Wu, G., Fu, Q., Ge, H., Liu, S., Li, X., & Cheng, B. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107098 · Cited by 4
Gadanecz, M., Fazekas, Z., Pálfy, G., Menyhárd, D. K., & Perczel, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512101 · Cited by 4
“Mutations in critical positions, mainly in the so-called P-loop (Figure 1) (the KRAS-G12C mutant is one of the most studied examples), lead to a shift towards the active form and consequently to the excessive activation of the signal transduction pathways by interfering with the binding of the assisting protein, GAP,…”
BackgroundKRAS Mutation Detection with (2S,4R)-4-[18F]FGln for Noninvasive PDAC Diagnosis
Liu, S., Liu, F., Hou, X., Zhang, Q., Ren, Y., Zhu, H., Yang, Z., & Xu, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00082 · Cited by 5
The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene
Garrido, J. A. M. G., Alcantara, K. M. M., Danac, J. M. C., Serrano, F. E. C., la Paz, E. M. C., & Garcia, R. L. (2021) · Cells · doi:10.3390/cells10123423 · Cited by 4
“These changes likely suggest an increased migratory potential as cytoskeletal reorganization and pseudopodial formation have been shown to be highly suggestive of a migratory phenotype, as these are among the preliminary steps taken by the cell to initiate movement [59].”
BackgroundChao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
Detection of PIP2 distributions in biological membranes using a peptide-based sensor
Menon, V. K., Wu, J., Alonzo, A. J., Scrudders, K. L., Rogers, K. A., Selvarajan, S., Walke, A., Pellicier-Caraballo, J., Kundu, R., Mondal, S., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110826 · Cited by 3
“To extend the cellular observations to MEFs expressing KRas mutants, we selected the G12 and G13 mutation hot-spots to focus on the mechanism of slowed Ras inactivation via interference of GTPase accelerating protein (GAP) binding (43).”
Hu, Z., Sha, Z., Martí, J., Guo, S., & Tao, S. (2026) · JACS Au · doi:10.1021/jacsau.5c01097 · Cited by 3
Erman, B. (2026) · Physical Biology · doi:10.1088/1478-3975/ae3e49 · Cited by 3
“23 (2026) 016005 B Erman models show G13 forms hydrogen bonds with GTP’s β – γ oxygen, and mutations alter nucleotide site conformation [48].”
Dong, C., Guo, F.-C., & Xue, J. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1901-2 · Cited by 3
“…past decades, molecular dynamics (MD) simulations have proved successful in understanding the structure and function of wild-type and mutated proteins (Hou and Yu 2007; Marino et al. 2015; Lu et al. 2016b), in particular those cancer-associated proteins (Lu et al. 2015a, 2016a; Hertig et al. 2016).”
BackgroundKRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Posttranslational Modifications Associated With Cancer and Their Therapeutic Implications
Bansal, A. K., Singh, L. R., & Kamli, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811913-6.00009-6 · Cited by 3
Identifying genes associated with resistance to KRAS G12C inhibitors via machine learning methods
Lin, X., Ma, Q., Chen, L., Guo, W., Huang, Z., Huang, T., & Cai, Y. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130484 · Cited by 4
Ilter, M., & Şensoy, Ö. (2019) · Scientific Reports · doi:10.1038/s41598-019-47481-1 · Cited by 3
The Endeavours in RAS Inhibition - the Past, Present, and Future
Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 4
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · Biomolecules · doi:10.3390/biom15060819 · Cited by 2
Bostancioglu, S. M., & Acar, A. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07137-y · Cited by 3
“Through a structure-based design approach, MRTX1133 was identified as a compound capable of restoring the dynamic conformation induced by the mutation in the KRAS4B switch II region to a stable, inactive conformation [58].”
Pastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 4
Ciftci, F. S., & Erman, B. (2026) · Physical Biology · doi:10.1088/1478-3975/ae9e79 · Cited by 2
Structural basis of ubiquitination mediated by protein splicing in early Eukarya
Chiarini, V., Fiorillo, A., Camerini, S., Crescenzi, M., Nakamura, S., Battista, T., Guidoni, L., Colotti, G., & Ilari, A. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129844 · Cited by 2
Progress on the development of prediction tools for detecting disease causing mutations in proteins
Gromiha, M. M., Pandey, M., Kulandaisamy, A., Sharma, D., & Ridha, F. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109510 · Cited by 2
Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors
Hoyek, C., Pirozzi, A., Jones, J. M., Rimassa, L., Sonbol, M. B., & Bekaii‐Saab, T. (2024) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2024.20.2.7 · Cited by 3
Ji, M., Zheng, G., Li, X., Zhang, Z., Jv, G., Wang, X., & Wang, J. (2017) · Journal of Molecular Modeling · doi:10.1007/s00894-017-3353-5 · Cited by 2
“map (DCCM) of the residue motions across the protein domains was calculated [37, 38].”
BackgroundAlagu Sankareswaran, S., Goutham, A., & Suma Mohan, S. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.07.001 · Cited by 2
Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades
Klochkov, S. G., Неганова, М. Е., & Aleksandrova, Y. R. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020050118 · Cited by 2
The structural basis of the oncogenic mutant K-Ras4B homodimersPreprint
Kosoglu, K., Omur, M. E., Jang, H., Nussinov, R., Keskin, Ö., & Gürsoy, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.07.285783 · Cited by 2
Self-citationJohnson, C. W., Lin, Y.-J., Reid, D. F., Parker, J. A., Dischinger, P. S., Graveel, C. R., Pavlopoulos, S., Steensma, M. R., Haigis, K. M., & Mattos, C. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3312728 · Cited by 2
Orthogonal resistance mechanisms of classical- and induced-proximity inhibitorsPreprint
Merz, M. L., Kailass, K., Pergu, R., Tran, K., Gupta, K., Severance, Z. C., Singh, S., Sreekanth, V., Law, B. K., Rosenblatt, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.10.652755 · Cited by 3
“While the Q61 mutation confers resistance against classical drugs by impairing GTPase activity and favoring the KRAS “on” state, 32 it may also sterically hinder the binding of the RMC-9805 molecular glue.”
Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72650-y · Cited by 1
Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation
Landgraf, A. D., Brenner, R., Ghozayel, M. K., Bum‐Erdene, K., González-Gutiérrez, G., & Meroueh, S. O. (2025) · ChemMedChem · doi:10.1002/cmdc.202400624 · Cited by 1
Merdler-Rabinowicz, R., Dadush, A., Patiyal, S., Rajagopal, P. S., Daya, G. N., Ben‐Aroya, S., Schäffer, A. A., Eisenberg, E., Ruppin, E., & Levanon, E. Y. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf016 · Cited by 2
“Among somatic mutations in KRAS, the most common one is G12D, which is also the most common KRAS mutation in carcinomas [ 49 ].”
Metadata
- Authors
- Lu, S., Jang, H., Nussinov, R., & Zhang, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Frederick National Laboratory for Cancer Research (US)
- Tel Aviv University (IL)
- Corresponding author
- Nussinov, Ruth
- Zhang, Jian
- Venue
- Scientific Reports
- Published
- 2016-02-23
- Volume
- 6
- Issue
- 1
- Pages
- 21949-21949
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4763299
- OpenAlex
- W2282990014
- Cited by
- 219
- References
- 69
- Citations by year
- 2026: 13 · 2025: 33 · 2024: 20 · 2023: 23 · 2022: 25 · 2021: 22 · 2020: 23 · 2019: 26 · 2018: 15 · 2017: 13 · 2016: 5
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (HHSN261200800001E)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E.)
- National Natural Science Foundation of China (81302698, 973 Program, HHSN261200800001E, 81473137, 2015CB910403, 81322046)
- Shanghai Rising-Star Program (13QA1402300)
- National Institutes of Health (#HHSN261200800001E, HHSN261200800001C)
- Program for New Century Excellent Talents in University (NCET-12-0355)
- National Key Research and Development Program of China (2015CB910403)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- K-Ras4B, oncogenic Ras mutations, G12D, G12V, small GTPases, GTP hydrolysis, GDP/GTP exchange, conformational change, GTPase-activating protein, RAS-driven cancers, molecular dynamics simulation
- MeSH terms
- Amino Acid Sequence, Arginine, Glutamine, Glycine, Guanosine Diphosphate, Guanosine Triphosphate, Humans, Hydrolysis, Mutation, Neoplasm Proteins, Gene Expression, Proto-Oncogene Proteins p21(ras), Protein Structure, Secondary, Catalytic Domain, Biocatalysis, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.